**PROMPT:**

Assessment / Plan: Pt is a uncontrolled type 2 diabetic with stage 3 chronic kidney disease. A nephrology consult and continued management of hypertension 

**RESPONSE:**

 __________ * The patient was taking the following medications for the past 30 days: Amlodipine 50 mg/month, Coumadin 20 mg/day, Furosemide 6 mg/day, Glibenclamide 10 mg/month, Humalog 40 mg/month, Insulin 200 IU/day, Humalog 70 mg/day, Humulin 25 mg/day, Novolog 50 mg/week, Novolog 50 mg/week, Novolog 50 mg/week, Novolog 50 mg/week, Novolog 50 mg/week, Novolog 5 mg/2 days, Novolog 2 mg/day, Novolog 0.5 mg/day, Octreotide 2 mg/day, Octreotide 2 mg/day, Octreotide 2 mg/day, Octreotide 500 IU/week, Nifedipine 10 mg/day, Novolog 50 mg/week, Novolog 50 mg/week, Novolog 80 mg/week, Novolog 12 mg/day in combination with a non-nephrine autoantibody, Novolog 6 mg/day. He was on a stable diet of approximately 3,000 calories per day. The patient was on a 4-day fast before this interview. The food intake was recorded. The caloric and macronutrient composition of the diet were determined.  Background: * This is a 12-day retrospective chart review of a patient with non-autoimmune chronic kidney disease. Patient's serum was obtained at diagnosis. Patient's urinary output was measured during fasting using continuous urine collection. There were no prior kidney disease-related complications. Patient's diet was consistent with the guidelines in the American Diabetes Association food pyramid. Physical activity level was monitored with the Short Form-36 Health Survey (SF-36) at the end of the first 6-month followup. (See Supplemental Tables 1, 2 and 3)  Symptoms / Signs:  Fasting plasma glucose, 2.7 mg/dl (normal range 2.5 to 4.0 mg/dl) Fasting blood pressure 95/54 mm Hg Laboratory Test Results Total Cholesterol, 6.6 mmol/l (normal range 4.8-7.0 mmol/l) Testosterone/epitestosterone, 15.2 pg/ml (normal range, 2.4-23.7 pg/ml) Fasting glucose, 7.3 mg/dl (normal range 3.8 to 7.6 mg